As of March 19, 2025, Tirzepatide can no longer be compounded in its original form due to the patents held by Eli Lilly on the medication. While compounding pharmacies were able to produce Tirzepatide-based formulations for a period of time under the FDA shortage exemption, that exemption ended when Tirzepatide was officially removed from the FDA shortage list in late 2024.

However, due to an ongoing lawsuit challenging the decision, Tirzepatide was temporarily placed back on the FDA shortage list while the courts heard arguments regarding its availability and production. In early 2025, a federal judge ruled against an injunction that would have allowed compounding pharmacies to continue producing Tirzepatide, citing that the medication was no longer in short supply and thus fell under Eli Lilly’s patent protection. This ruling effectively blocked the ability of compounding pharmacies to manufacture Tirzepatide in its original form, creating a new challenge for patients who relied on the compounded version for affordability and access.

​

The New Formulation: Tirzepatide + Methylcobalamin (Vitamin B12)

We want to reassure our patients that the base formulation of Tirzepatide has not changed—it remains exactly the same. In response to recent restrictions, compounding pharmacies have simply added Methylcobalamin (Vitamin B12) to the existing formulation. This strategic enhancement allows us to continue offering this highly effective treatment while also improving the patient experience.

This update offers two major benefits:

• Continued Access to Treatment – By incorporating B12, compounding pharmacies have created a legally distinct version of Tirzepatide that complies with regulatory requirements and avoids infringement on Eli Lilly’s patents. This ensures that patients already benefiting from GLP-1 therapy can continue their treatment without disruption.

• Enhanced Convenience & Wellness Support – Methylcobalamin (Vitamin B12) has always been a key part of our weight loss protocol for its ability to boost energy, support metabolism, and improve overall well-being. Now, instead of requiring a separate injection, patients receive both Tirzepatide and B12 in one simple weekly dose, reducing the number of injections and enhancing the effectiveness of their treatment.

This small but meaningful update marks the next step in compounded GLP-1 therapies—providing a safe, effective, and convenient option for medical weight loss. At Mountain West Medical Spa, we’re proud to stay at the forefront of these innovations and remain committed to offering our patients the most advanced and accessible treatment solutions available.